Elite in Relapsing Multiple Sclerosis (RMS)

Heinz Wiendl

Freiburg, BW, DE 
Elite in Relapsing Multiple Sclerosis (RMS)
Freiburg, BW, DE 
OverviewLocationsClinical Research

Overview

Heinz Wiendl practices in Freiburg, Germany. Mr. Wiendl is rated as an Elite expert by MediFind in the treatment of Relapsing Multiple Sclerosis (RMS). His top areas of expertise are Multiple Sclerosis (MS), Relapsing Multiple Sclerosis (RMS), Encephalitis, Thrombectomy, and Thymectomy.

His clinical research consists of co-authoring 580 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 107 articles and participated in 1 clinical trial in the study of Relapsing Multiple Sclerosis (RMS).

Gender
Male

Locations

Freiburg, BW 79106, Germany
Other Locations
Muenster, NW, Germany
Heidelberg, BW, Germany
Berlin, BE, Germany
Salem, BW 79104, Germany
Munich, BY, Germany
Gutenberg, RP, Germany
Hannover, NI, Germany
Tuebingen, BW, Germany
Germany
Regensburg, BY, Germany
Wuerzburg, BY, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A 2-year Prospective Study to Evaluate the Onset of Action of Mavenclad® in Subjects With Highly Active Relapsing Multiple Sclerosis (MAGNIFY)
A 2-year Prospective Study to Evaluate the Onset of Action of Mavenclad® in Subjects With Highly Active Relapsing Multiple Sclerosis (MAGNIFY)
Enrollment Status: Completed
Publish Date: March 16, 2023
Intervention Type: Drug
Study Drug: Mavenclad®
Study Phase: Phase 4
Essai de Phase IV, Multicentrique, Ouvert, Visant à Tester la différence d'efficacité du Natalizumab, Versus le Fingolimod, 2 médicaments Ayant Une AMM Pour le Traitement de la sclérose en Plaques
Essai de Phase IV, Multicentrique, Ouvert, Visant à Tester la différence d'efficacité du Natalizumab, Versus le Fingolimod, 2 médicaments Ayant Une AMM Pour le Traitement de la sclérose en Plaques
Enrollment Status: Completed
Publish Date: August 25, 2020
Intervention Type: Procedure
View 1 Less Clinical Trial

580 Total Publications

AhR signaling in skin-resident CD207+ cells is involved in UV-B-induced amelioration of neuroinflammation.
AhR signaling in skin-resident CD207+ cells is involved in UV-B-induced amelioration of neuroinflammation.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: September 02, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Wiendl's expertise for a condition
ConditionClose
View All 17 Advanced Conditions
View All 84 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile